Loading menu...

Prostate Cancer (PCa) will affect most men if they live long enough and PCa is one of the leading causes of cancer deaths.

  		Each year over 200,000 men are newly diagnosed with PCa in North America.  CPC-100 is for asympto-matic 'watchfull waiting' PCa patients who fail prostate removal & hormone therapy, with no approved drug availble to them. 

Drugs for  therapy-resitant solid cancers & hypoxic conditions 

 Colby's mission is to develop & sell drugs for hypoxia & therapy-resistant tumors
Colby drugs resore therapy-sensitivity or normoxia

Pipeline

Platform

Platform Technology 

Colby and collaboratory have identified pathways and drugs which restore normoxia and reverse therapy-resistance in solid tumors. Colby is using this platform technology to develop safe and potent new drugs and companion diagnostics for therapy-resistant solid cancers and hypoxic conditions.

 

More information on Colby's platform technology is available upon request.